TAK Earnings Prediction
The chart below shows how TAK performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TAK sees a -0.41% change in stock price 10 days leading up to the earnings, and a -0.75% change 10 days following the report. On the earnings day itself, the stock moves by +1.47%. This data can give you a slight idea of what to expect for the next quarter's release.
TAK Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.18T
12.75%
-2.65%
Gross Margin
54.66%
0.24%
-3.24%
Operating Margin
15.97%
176.78%
1.27%
Net Margin
7.83%
270.22%
-0.76%
EPS
57.19
286.41%
-4.59%
No Data Available
TAK Earnings Analysis
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share o Corporation (TAK.N) Earnings Conference Call
Positive
Revenue Growth Highlights: First half revenue grew 5% at constant exchange rate, driven by our Growth & Launch product, which grew 18.7% at constant exchange rate and now accounts for 47% of total revenue.
Core Operating Profit Margin: Core operating profit margin was 30.2%, benefiting from product mix, phasing of R&D investment as well as the early impact of our efficiency programs.
Operating Cash Flow Increase: Operating cash flow was ¥451.3 billion, up 54.9% year-on-year, reflecting our strong profit growth as well as improvements in working capital.
Strong Growth in Product Portfolio: We achieved robust performance broadly across our Growth & Launch product portfolio, demonstrating significant growth at 18.7% at CER in the first half.
Product Launch Success: We have seen a strong uptake in our newly launched products, exceeding revenue expectations, and approvals in the European Union and Japan support the geographic expansion of these new treatments.
Negative
VYVANSE Sales Decline: VYVANSE declined 29% in the U.S. and 18% globally, indicating slower-than-expected erosion in the U.S.
Operating Profit Margin Analysis: Core operating profit margin was 30.2%, benefiting from product mix and R&D phasing, but still reflects challenges in cost management.
R&D Investment Decline: R&D investment decreased by 8.3% at CER, primarily due to the termination of certain programs during the pipeline privatization at the end of FY '23.
Operating Profit Surge: Operating profit was ¥350.6 billion, growing almost 200%, but this was influenced by less impairment and other one-time costs compared to the last fiscal year.
Liquidity Concerns Amid Profit Growth: Adjusted free cash flow was ¥247.5 billion, indicating potential liquidity issues despite strong operating profit growth.
TAK FAQs
How does TAK typically perform around its earnings report dates?
Is Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
TAK Earning Call Sentiment
Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript
1.0x
00:00
00:00
TAK.N
0.2%Positive
The earnings call presents a mixed picture. Financial performance shows strong revenue and profit growth, but regulatory challenges, increased costs, and competitive pressures pose risks. The Q&A highlights management's confidence in certain products but also reveals competitive challenges and unclear guidance on some fronts. Positive elements like revenue growth and free cash flow are offset by concerns about regulatory impacts and competition. Overall, the sentiment is neutral, as positive financials are balanced by potential risks and uncertainties.
